Paying Royalties Beyond Patent Life Still Illegal
In case you missed it, earlier this year the United States Supreme Court upheld its…
partner
Dan’s practice focuses on the business transactions important to pharmaceutical and biotech companies, including licensing and commercial transactions, FDA-related regulatory matters, asset acquisitions and divestitures, supply agreements, product development agreements and strategic alliances. Dan previously served as outside counsel to life sciences companies and in in-house counsel roles for Eli Lilly and Company, AAIPharma, Inc., Xanodyne Pharmaceuticals, Inc. and Xcellerex, Inc.
Profile Details
Recognition, Affiliations & Memberships
- North Carolina State Bar
- Pinnacle Award (Eli Lilly)
- Corporate Business Development Award of Merit (Eli Lilly)
- Sourcing Innovation Energizer Award (Eli Lilly)
- American Jurisprudence Award
- Advisory Committee, UF Sid Martin Biotechnology Institute
- Board Member, SEBIO
- Former Chairman, LES RTP Chapter
- Managing Partner 2017-2018
- Former member, BioLabs North Carolina Advisory Board
- Director, First Flight Venture Center (2020-present)
- Member, VCU Commercialization Advisory Board
Education
- J.D., summa cum laude, Indiana University School of Law, 1993
- B.A., Wabash College, 1989
Admissions
- North Carolina
- Indiana
Select Publications
- When Small Pharma Buys a Big Pharma Product, North Carolina Magazine, November 2006
- Negotiating a Manufacturing Agreement: What do you need to know?, Contract Pharma, March 2007
- Mediummune v. Genentech and its Aftermath, Patent Strategy and Management, June 2007
Articles & Resources
Articles
- Hutchison PLLC Joins with LaunchBio to Support Entrepreneurs at BioLabs North Carolina
October 26, 2017 - Client Alert: Newly-Passed 21st Century Cures Act — Immediate Action Might Be Required
January 31, 2017 - Hutchison PLLC takes on the #ALSicebucketchallenge
August 25, 2014 - Hutchison Welcomes Dan O’Korn
March 19, 2012
Areas of Practice
Recent Blog Posts
